Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

NCT02906696 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Terminated per PI's request due to competing priorities.

Conditions

Blasts Under 15 Percent of Bone Marrow Nucleated Cells
Blasts Under 15 Percent of Peripheral Blood White Cells
Blasts Under 30 Percent of Bone Marrow Nucleated Cells
Blasts Under 30 Percent of Peripheral Blood White Cells
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions

DRUG: Bosutinib
OTHER: Laboratory Biomarker Analysis

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]